Adicet Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
63.2%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$8.87next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Prula-cel Potential Pivotal Study Initiation | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, cash equivalents, and short-term investments Quarterly137.6MTarget: Sufficient to fund operating expenses into the second half of 2027
Prula-cel Phase 1 Autoimmune Patient Enrollment Quarterly20.0Target: At least 20 patients with a minimum of six months follow-up for mid-2026 update
Watch Items
- Prula-cel Phase 1 clinical update in LN and SLE patientsTrigger: Mid-2026 data releaseAction: Evaluate safety, efficacy, and outpatient dosing feasibility to support pivotal trial design
- FDA interaction for prula-cel pivotal trial designTrigger: Q2 2026 meetingAction: Align on Phase 2 pivotal trial design and initiate start-up activities in 2H 2026
- ADI-212 regulatory filing for mCRPCTrigger: Q3 2026 submissionAction: Prepare for Phase 1 clinical trial enrollment starting in Q4 2026
Research as of 19 Jun 2026